Apeloa Pharmaceutical Co.,Ltd
000739
Κατάταξη σε μετοχές
#4291
Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical... Apeloa Pharmaceutical Co.,Ltd operates as a comprehensive pharmaceutical enterprise, specializing in the discovery, development, production, and global distribution of a diverse range of medicinal products. Its market reach spans China and various international territories. The company strategically focuses its product portfolio on several critical medical fields, including cardiovascular and cerebrovascular health, anti-infective treatments, antiviral therapies, and oncology (cancer treatment), alongside other therapeutic categories. Apeloa's offerings encompass finished pharmaceutical preparations, raw material intermediates (active pharmaceutical ingredients and their precursors), and veterinary medicines. These products are primarily recognized and sold under key brands such as Tianliwei, Beshin, Yosemade, and Jutai, among others. Furthermore, the company extends its expertise to other pharmaceutical businesses by providing contract research, development, and manufacturing (CDMO) services. The corporate headquarters for Apeloa Pharmaceutical Co.,Ltd are located in Dongyang, China.
Τιμή μετοχής
$3.13
Κεφαλαιοποίηση
$3.62B
Αλλαγή (1 ημέρα)
-1.42%
Αλλαγή (1 έτος)
46.59%
Χώρα
CN
Εμπόριο Apeloa Pharmaceutical Co.,Ltd (000739)
Κατηγορία
Healthcare
Κέρδη για την Apeloa Pharmaceutical Co.,Ltd (000739)
Κέρδη τον Jun 2026 TTM: $149.15M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Apeloa Pharmaceutical Co.,Ltd, τα τρέχοντα κέρδη της εταιρείας είναι $149.15M. Το 2024, η εταιρεία παρουσίασε κέρδη $164.85M, μείωση σε σύγκριση με των κερδών του 2023 που ήταν $170.18M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την Apeloa Pharmaceutical Co.,Ltd από 2000 έως 2026
Κέρδη στο τέλος κάθε έτους
| Έτος | Κέρδη | Αλλαγή |
|---|---|---|
| 2026 (TTM) | $149.15M | -2.13% |
| 2025 | $152.39M | -7.56% |
| 2024 | $164.85M | -3.13% |
| 2023 | $170.18M | 15.99% |
| 2022 | $146.72M | -16.29% |
| 2021 | $175.28M | 19.13% |
| 2020 | $147.13M | 61.66% |
| 2019 | $91.01M | 35.45% |
| 2018 | $67.19M | 28.72% |
| 2017 | $52.20M | 8.08% |
| 2016 | $48.30M | 26.97% |
| 2015 | $38.04M | -37.54% |
| 2014 | $60.90M | 79.55% |
| 2013 | $33.92M | 25.69% |
| 2012 | $26.99M | 83.30% |
| 2011 | $14.72M | 255.37% |
| 2010 | $4.14M | -25.11% |
| 2009 | $5.53M | 37.62% |
| 2008 | $4.02M | -6.10% |
| 2007 | $4.28M | -48.53% |
| 2006 | $8.32M | 30.32% |
| 2005 | $6.38M | 8.44% |
| 2004 | $5.89M | -2.73% |
| 2003 | $6.05M | -2.07% |
| 2002 | $6.18M | -300.22% |
| 2001 | $-3.09M | 423.46% |
| 2000 | $-589.59K | 0.00% |
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών
| Εταιρεία | Κέρδη | Διαφορά Κερδών | Χώρα |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 1,083.07% |
IN
|
